HC Wainwright Cuts AnaptysBio (NASDAQ:ANAB) Price Target to $52.00

AnaptysBio (NASDAQ:ANAB) had its target price reduced by HC Wainwright from $55.00 to $52.00 in a research note released on Wednesday,Benzinga reports. They currently have a buy rating on the biotechnology company’s stock. HC Wainwright also issued estimates for AnaptysBio’s Q4 2024 earnings at ($1.70) EPS, FY2024 earnings at ($6.18) EPS, FY2025 earnings at ($7.91) EPS, FY2026 earnings at ($10.47) EPS, FY2027 earnings at ($10.55) EPS and FY2028 earnings at ($9.66) EPS.

A number of other equities analysts have also recently weighed in on the stock. Guggenheim upped their price objective on shares of AnaptysBio from $75.00 to $90.00 and gave the company a “buy” rating in a research report on Monday, October 21st. UBS Group raised their price objective on AnaptysBio from $23.00 to $33.00 and gave the company a “neutral” rating in a research note on Wednesday, October 30th. Wedbush reaffirmed an “outperform” rating and issued a $42.00 target price on shares of AnaptysBio in a research report on Wednesday. Truist Financial raised their price target on shares of AnaptysBio from $20.00 to $30.00 and gave the stock a “hold” rating in a research report on Thursday, August 15th. Finally, JPMorgan Chase & Co. upped their price target on shares of AnaptysBio from $69.00 to $75.00 and gave the company an “overweight” rating in a report on Wednesday, August 7th. Two research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $55.45.

AnaptysBio Trading Down 0.8 %

Shares of AnaptysBio stock opened at $21.31 on Wednesday. AnaptysBio has a twelve month low of $13.36 and a twelve month high of $41.31. The stock has a market cap of $584.53 million, a price-to-earnings ratio of -3.36 and a beta of -0.24. The company has a fifty day moving average price of $32.66 and a 200 day moving average price of $29.84.

AnaptysBio (NASDAQ:ANAB) last issued its quarterly earnings data on Tuesday, November 5th. The biotechnology company reported ($1.14) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.72) by $0.58. AnaptysBio had a negative net margin of 558.25% and a negative return on equity of 255.68%. The company had revenue of $30.02 million during the quarter, compared to the consensus estimate of $7.92 million. Analysts forecast that AnaptysBio will post -6.84 earnings per share for the current year.

Insider Transactions at AnaptysBio

In related news, insider Paul F. Lizzul sold 1,500 shares of the business’s stock in a transaction dated Monday, September 23rd. The shares were sold at an average price of $38.67, for a total transaction of $58,005.00. Following the completion of the sale, the insider now owns 15,398 shares of the company’s stock, valued at $595,440.66. This represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In related news, insider Eric J. Loumeau sold 8,720 shares of the firm’s stock in a transaction that occurred on Monday, September 16th. The stock was sold at an average price of $39.82, for a total value of $347,230.40. Following the sale, the insider now owns 7,020 shares of the company’s stock, valued at approximately $279,536.40. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Paul F. Lizzul sold 1,500 shares of the business’s stock in a transaction that occurred on Monday, September 23rd. The shares were sold at an average price of $38.67, for a total value of $58,005.00. Following the transaction, the insider now owns 15,398 shares of the company’s stock, valued at $595,440.66. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 22,440 shares of company stock worth $892,936. 33.70% of the stock is currently owned by insiders.

Institutional Investors Weigh In On AnaptysBio

Hedge funds have recently added to or reduced their stakes in the stock. Allspring Global Investments Holdings LLC acquired a new stake in shares of AnaptysBio in the 1st quarter worth about $38,000. Mirae Asset Global Investments Co. Ltd. acquired a new stake in shares of AnaptysBio in the first quarter valued at approximately $265,000. Susquehanna Fundamental Investments LLC acquired a new stake in shares of AnaptysBio in the first quarter valued at approximately $1,221,000. Acadian Asset Management LLC bought a new stake in shares of AnaptysBio during the first quarter valued at approximately $420,000. Finally, Platinum Investment Management Ltd. acquired a new position in shares of AnaptysBio during the first quarter worth approximately $1,490,000.

About AnaptysBio

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.